Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SOL-258
- Development stage
- Preclinical
- Lead developer
- Sola Biosciences
- Modality
- Gene Therapies
01
Overview
SOL-258 is an investigational gene therapy developed by Sola Biosciences. It is being studied for the treatment of neurodegenerative diseases, with primary indications including Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). The drug utilizes a gene therapy modality, but specific details about its vector, transgene, or precise mechanism of action have not been disclosed in public sources. As of the latest updates, SOL-258 remains in preclinical development and has not received regulatory approval for any indication[1][2].
Beyond the preview
Go deeper on SOL-258.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SOL-258.